Because PDA (BPC-157-Arginine) remains an investigational peptide, formulation selection, dosing, and duration should always be determined by an appropriately licensed healthcare professional
Subcutaneous Injection Sites : Abdomen (2 inches from navel) Upper thighs Upper arms Near injury site (within 2-3 inches for localized healing) Intramuscular Options : Directly into affected muscle groups Shoulder deltoids Gluteal muscles Injection Equipment : 29-31 gauge insulin syringes 0.5-1ml capacity 12.7mm (1/2 inch) for subcutaneous 25mm (1 inch) for intramuscular Reconstitution Protocol BPC-157 typically comes as lyophilized powder requiring careful reconstitution: Use bacteriostatic water (0.9% benzyl alcohol) Add 2ml bacteriostatic water to 5mg vial Results in 2.5mg/ml concentration Gently swirl, avoid vigorous shaking Store reconstituted solution refrigerated Storage Requirements Unreconstituted : Room temperature, away from light and moisture Reconstituted : Refrigerate at 2-8C (36-46F) Stability : Use within 28 days of reconstitution Transport : Keep cool, avoid temperature extremes Optimal Timing and Administration Strategies Timing for Maximum Effectiveness Split Dosing Benefits : Dividing daily dose into 2-3 administrations maintains more consistent peptide levels and enhances healing throughout the day
This guide breaks down the exact protocol structure we use at our peptide clinic in Doral, FL: dose by administration route, dose by use case, cycle length and rest periods, the mcg-to-units-to-mL math patients ask about every week, and how BPC-157 dosage changes when it is stacked with TB-500 in the Wolverine protocol
Disclaimer: All peptides are for laboratory research use only
Is BPC-157 authorised as a UK medicine
Stakeholders wishing to translate the List into other languages are kindly asked to signal their interest to [email protected]
